Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicenter retrospective study

BACKGROUND:\r\nInterstitial lung disease (ILD) is the most severe extra-articular manifestation of rheumatoid arthritis (RA). Although it is responsible of 10-20% of all RA mortality, no controlled studies are available for the treatment of RA-ILD and its therapeutic approach is still debated.\r\n\r\nAIMS:\r\nIn this study, we analysed the evolution of ILD in a population of RA patients treated with tocilizumab (TCZ).\r\n\r\nMETHODS:\r\nIn this national multicenter study, we retrospectively collected patients with RA-ILD treated with at least one dose of TCZ. For each patient, disease activity and serological data were evaluated. Moreover, we analysed the evolution of high-resolution computed tomography (HRCT) and pulmonary function tests, including forced vital capacity (FVC) and diffusing capacity of carbon monoxide (DLCO).\r\n\r\nRESULTS:\r\nTwenty-eight RA-ILD patients were identified (females/males 18/10, mean age 61.6 years), with a mean follow-up for TCZ therapy of 30 months. At the end of follow-up, FVC remained stable in 14 patients (56%), improved in 5 (20%) and worsened in 6 (24%). DLCO remained stable in 14 patients (56%), improved in 5 (20%) and worsened in 6 (24%), even though in 3 patients DLCO and FVC showed an opposite trend. HRCT remained stable in the majority of cases (25), worsened in 2 patients with a usual interstitial pneumonia pattern, improved in only one case with a nonspecific interstitial pneumonia pattern.\r\n\r\nCONCLUSIONS:\r\nThe management of RA-ILD patients remains a critical unmet need. TCZ demonstrated a good safety profile in patients with RA-ILD and a potential effect on the stabilization of the lung involvement.